Display options
Cite
Liedgens H, Obradovic M, Nuijten M. Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res. 2013;5:597-609doi: 10.2147/CEOR.S51776.
Liedgens, H., Obradovic, M., & Nuijten, M. (2013). Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia. ClinicoEconomics and outcomes research : CEOR, 5597-609. https://doi.org/10.2147/CEOR.S51776
Liedgens, Hiltrud, et al. "Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia." ClinicoEconomics and outcomes research : CEOR vol. 5 (2013): 597-609. doi: https://doi.org/10.2147/CEOR.S51776
Liedgens H, Obradovic M, Nuijten M. Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res. 2013 Nov 25;5:597-609. doi: 10.2147/CEOR.S51776. PMID: 24348056; PMCID: PMC3848379.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2013 Nov 25;5:597-609. doi: 10.2147/CEOR.S51776.

Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia.

ClinicoEconomics and outcomes research : CEOR

Hiltrud Liedgens, Marko Obradovic, Mark Nuijten

Affiliations

  1. Grunenthal GmbH, Aachen, Germany.
  2. Ars Accessus Medica, Amsterdam, the Netherlands.

PMID: 24348056 PMCID: PMC3848379 DOI: 10.2147/CEOR.S51776

Abstract

BACKGROUND: Post-herpetic neuralgia (PHN) is the most common and most debilitating complication of herpes zoster, and involves considerable associated costs.

OBJECTIVE: This paper presents results from nine health economic studies undertaken in eight European countries that compared lidocaine medicated plaster with gabapentin and/or pregabalin in PHN. It aims to support the increasing need for published cost-effectiveness data for health care decision-making processes in Europe.

METHODS: All studies were based on a similar core Markov model with data derived from clinical trials, local Delphi panels, and official national price and tariff lists. The main outcome measure was cost per quality-adjusted life year gained; time without pain or intolerable adverse events was also included as a secondary outcome measure. All studies focused on an elderly population of patients with PHN who had insufficient pain relief with standard analgesics and could not tolerate or had contraindications to tricyclic antidepressants.

RESULTS: Despite considerable differences in many of the variables used, the results showed remarkable similarity and suggested that use of lidocaine medicated plaster offered cost-savings in many of the countries studied, where it proved a highly cost-effective alternative to both gabapentin and pregabalin.

CONCLUSION: Lidocaine medicated plaster is a cost-effective alternative to gabapentin and pregabalin in the treatment of PHN. These savings are largely the result of the superior safety profile of the lidocaine medicated plaster.

Keywords: cost-effectiveness; lidocaine; plaster; post-herpetic neuralgia; zoster

References

  1. Clin Interv Aging. 2012;7:249-55 - PubMed
  2. Clin Drug Investig. 2008;28(9):583-601 - PubMed
  3. Psychosomatics. 2004 Sep-Oct;45(5):371-7 - PubMed
  4. Clin Drug Investig. 2009;29(6):393-408 - PubMed
  5. Clin Ther. 2007 Jul;29(7):1491-507 - PubMed
  6. Ann N Y Acad Sci. 2006 Nov;1088:164-86 - PubMed
  7. J Pain. 2007 May;8(5):396-404 - PubMed
  8. Curr Med Res Opin. 2011 May;27(5):939-50 - PubMed
  9. Arch Intern Med. 2003 Mar 10;163(5):628 - PubMed
  10. Int J Emerg Med. 2011 Jun 02;4(1):22 - PubMed
  11. Pain Med. 2002 Dec;3(4):324-32 - PubMed
  12. Pain. 2001 Nov;94(2):215-224 - PubMed
  13. J Pain. 2006 Feb;7(2):119-28 - PubMed
  14. BMC Fam Pract. 2010 Nov 05;11:85 - PubMed
  15. Ann Neurol. 1995 Feb;37(2):246-53 - PubMed
  16. Curr Med Res Opin. 2009 Jul;25(7):1663-76 - PubMed
  17. Pain. 1996 Oct;67(2-3):241-51 - PubMed
  18. Pain. 2007 Dec 5;132(3):237-251 - PubMed
  19. Drugs Aging. 2007;24(1):1-19 - PubMed
  20. Br J Clin Pharmacol. 2006 Feb;61(2):218-23 - PubMed
  21. Clin J Pain. 2005 Jul-Aug;21(4):302-10 - PubMed
  22. Curr Med Res Opin. 2004;20 Suppl 2:S21-8 - PubMed
  23. Drug Saf. 2004;27(15):1217-33 - PubMed
  24. BMC Anesthesiol. 2011 Dec 19;11:25 - PubMed
  25. Pain. 2004 May;109(1-2):26-35 - PubMed
  26. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD007393 - PubMed
  27. Pain. 1996 Apr;65(1):39-44 - PubMed
  28. Neurology. 2003 Apr 22;60(8):1274-83 - PubMed
  29. Drugs Aging. 2003;20(11):817-32 - PubMed
  30. Clin J Pain. 2002 Nov-Dec;18(6):350-4 - PubMed
  31. Pain. 2003 Nov;106(1-2):151-8 - PubMed
  32. JAMA. 1998 Dec 2;280(21):1837-42 - PubMed
  33. Neurology. 1995 Dec;45(12 Suppl 8):S52-3 - PubMed
  34. Neurology. 2004 Sep 28;63(6):959-65 - PubMed
  35. Pain. 1999 Apr;80(3):533-538 - PubMed
  36. Expert Opin Pharmacother. 2004 Mar;5(3):551-9 - PubMed
  37. Pain Res Manag. 2011 Jul-Aug;16(4):259-63 - PubMed
  38. Curr Med Res Opin. 2009 May;25(5):1295-305 - PubMed
  39. Vaccine. 2007 Oct 23;25(43):7598-604 - PubMed
  40. Curr Med Res Opin. 2012 Jun;28(6):937-51 - PubMed
  41. PLoS Med. 2005 Jul;2(7):e164 - PubMed
  42. Curr Med Res Opin. 2012 Aug;28(8):1337-46 - PubMed
  43. Curr Med Res Opin. 2012 Jun;28(6):901-9 - PubMed
  44. Clin J Pain. 2002 Sep-Oct;18(5):297-301 - PubMed
  45. J Med Econ. 2010;13(3):482-91 - PubMed
  46. Acta Neurol Scand. 2011 May;123(5):295-309 - PubMed
  47. Age Ageing. 2006 Mar;35(2):132-7 - PubMed
  48. Herpes. 2007 Sep;14 Suppl 2:35-9 - PubMed
  49. Eur J Neurol. 2010 Sep;17(9):1113-e88 - PubMed
  50. BMC Infect Dis. 2010 Aug 03;10:230 - PubMed
  51. Palliat Med. 2004 Jan;18(1):5-11 - PubMed
  52. Clin Drug Investig. 2010;30(2):71-87 - PubMed
  53. J Pain Res. 2012;5:7-13 - PubMed
  54. J Palliat Med. 2011 Jun;14(6):765-73 - PubMed

Publication Types